Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209(6):727–32.

Article  PubMed  Google Scholar 

Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381(6):552–65.

Article  CAS  PubMed  Google Scholar 

Beard C, Sheps S, Kurland L, et al. editors. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proceedings; 1983.

Sutton M, Sheps S, Lie J, editors. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clinic Proceedings; 1981.

Aghamir SMK, Heshmat R, Ebrahimi M, et al. Liquid Biopsy: the unique test for chasing the Genetics of Solid tumors. Epigenetics Insights. 2020;13:2516865720904052.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Li Y, Guan X, et al. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma. Mol Cancer. 2018;17(1):1–6.

Article  Google Scholar 

Khatami F, Tavangar SM. Current diagnostic status of pheochromocytomaand future perspective: a mini review. Iran J Pathol. 2017;12(3):313.

Article  PubMed  PubMed Central  Google Scholar 

Kulis M, Esteller M. DNA methylation and cancer. Advances in genetics. Volume 70. Elsevier; 2010. pp. 27–56.

Khatami F, Mohammadamoli M, Tavangar SM. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs). Endocr Regul. 2018;52(1):41–54.

Article  PubMed  Google Scholar 

Nazar E, Khatami F, Saffar H, et al. The emerging role of Succinate Dehyrogenase genes (SDHx) in Tumorigenesis. Int J Hematology-Oncology Stem Cell Res. 2019;13(2):72.

Google Scholar 

Backman S, Maharjan R, Falk-Delgado A, et al. Global DNA methylation analysis identifies two Discrete clusters of pheochromocytoma with distinct genomic and genetic alterations. Sci Rep. 2017;7:44943.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fatemeh Khatami BL, Ramin Heshmat S, Nasiri H, Saffar G, Shafiee. Azam Mossafa, Seyed Mohammad Tavangar. Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma. Iranian Journal of Pathology. 2018;In Press.

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505.

Article  PubMed  PubMed Central  Google Scholar 

Chatterjee A, Rodger EJ, Eccles MR, editors. Epigenetic drivers of tumourigenesis and cancer metastasis. Seminars in cancer biology. Elsevier; 2018.

Ma M, Zhu H, Zhang C et al. Liquid biopsy—ctDNA detection with great potential and challenges. Annals Translational Med. 2015;3(16).

Khatami F, Larijani B, Tavangar SM. The presence of tumor extrachomosomal circular DNA (ecDNA) as a component of liquid biopsy in blood. Med Hypotheses. 2018;114:5–7.

Article  CAS  PubMed  Google Scholar 

Khatami F, Aghaii M, Aghamir SMK. Prime editing: the state-of-the-art of genome editing. Meta Gene. 2020;24:100661.

Article  Google Scholar 

Tamehri Zadeh SS, Taheri D, Shivarani S, et al. Liquid biopsy in prostate Cancer diagnosis and prognosis: a narrative review. Translational Res Urol. 2020;2(4):139–46.

Google Scholar 

Letouzé E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23(6):739–52.

Article  PubMed  Google Scholar 

Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metabolism. 2012;97(6):E954–62.

Article  CAS  Google Scholar 

Ahmadi K, Fasihi Ramandi M. Evaluation of Antibacterial and Cytotoxic effects of K4 synthetic peptide. Translational Res Urol. 2021;3(2):59–66.

Google Scholar 

Astuti D, Morris M, Krona C, et al. Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. Br J Cancer. 2004;91(10):1835–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grau E, Oltra S, Orellana C, et al. There is no evidence that the SDHB gene is involved in neuroblastoma development. Oncol Res Featuring Preclinical Clin Cancer Ther. 2005;15(7–8):393–8.

CAS  Google Scholar 

Loriot C, Domingues M, Berger A, et al. Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget. 2015;6(32):32955–65.

Article  PubMed  PubMed Central  Google Scholar 

Ricci R, Martini M, Ravegnini G, et al. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clin Epigenetics. 2019;11(1):2.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Pang Y, Caisova V, et al. Targeting NRF2-governed glutathione synthesis for SDHB-mutated pheochromocytoma and paraganglioma. Cancers. 2020;12(2):280.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lamy C, Hadoux J, Durand S, et al. Preclinical evaluation of new therapeutic strategies on SDHB invalidated clones from human pheochromocytoma cells. AACR; 2019.

Rashedi S. Landscape of circular ribonucleic acids in Urological Cancers. Translational Res Urol. 2021;3(2):45–7.

Google Scholar 

Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41(6):805–14.

Article  CAS  PubMed  Google Scholar 

Remacha L, Comino-Méndez I, Richter S, et al. Targeted exome sequencing of Krebs cycle genes reveals candidate cancer–predisposing mutations in pheochromocytomas and paragangliomas. Clin Cancer Res. 2017;23(20):6315–24.

Article  CAS  PubMed  Google Scholar 

Shi C, Zeng Z, Zhao D, et al. Application of SDHB and SDHC immunohistochemistry in the differentiation of malignant and benign pheochromocytoma and paraganglioma. Chin J Endocrinol Metabolism. 2018;34(6):472–8.

Google Scholar 

Karimaei S, Oliveira Reis L. Cytotoxicity and apoptotic effect of Nisin as an effective bacteriocin on the Cancer cells. Translational Res Urol. 2020;2(2):45–7.

Google Scholar 

Richter S, Klink B, Nacke B, et al. Epigenetic mutation of the succinate dehydrogenase C promoter in a patient with two paragangliomas. J Clin Endocrinol Metabolism. 2016;101(2):359–63.

Article  CAS  Google Scholar 

Smestad J, Hamidi O, Wang L, et al. Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma. Oncotarget. 2018;9(5):6109.

Article  PubMed  Google Scholar 

Narita T, Yamaguchi Y, Yano K, et al. Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol Cell Biol. 2003;23(6):1863–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Cubas AA, Korpershoek E, Inglada-Pérez L, et al. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers. Clin Cancer Res. 2015;21(13):3020–30.

Article  PubMed  Google Scholar 

Goncalves J, Lussey-Lepoutre C, Favier J, et al. editors. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Annales d’endocrinologie. Elsevier; 2019.

Björklund P, Backman S. Epigenetics of pheochromocytoma and paraganglioma. Mol Cell Endocrinol. 2018;469:92–7.

Article  PubMed  Google Scholar 

Oishi T, Iino K, Okawa Y, et al. DNA methylation analysis in malignant pheochromocytoma and paraganglioma. J Clin Translational Endocrinol. 2017;7:12–20.

Article  Google Scholar 

Job S, Georges A, Burnichon N, et al. Transcriptome analysis of lncRNAs in pheochromocytomas and paragangliomas. J Clin Endocrinol Metabolism. 2020;105(3):898–907.

Article  Google Scholar 

Nicolas M, Dahia P. Predictors of outcome in phaeochromocytomas and paragangliomas. F1000Research. 2017;6.